OBJECTIVES:Galantamine is an acetylcholinesterase inhibitor and an allosteric modulator of the alpha4beta2 and alpha7 nicotinic receptors. There are several case reports describing the potential benefits of galantamine for negative symptoms associated with schizophrenia. This secondary analysis describes the effects of galantamine on psychopathology in people with schizophrenia. METHODS:Subjects with clinically stable chronic schizophrenia were randomized to adjunctive galantamine (24 mg/d) or placebo in a 12-week double-blind trial. Symptomatology was assessed with the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impression Scale. The Scale for the Assessment of Negative Symptoms (SANS) was used to measure negative symptoms. RESULTS:Eighty-six patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of schizophrenia or schizoaffective disorder taking a stable dose of antipsychotic medications were randomized to adjunctive treatment with study drug (galantamine, n = 42; placebo, n = 44); 73 subjects completed the study (galantamine, n = 35; placebo, n = 38). No significant differences were found on BPRS total score (P = 0.585) or BPRS subfactor scores. Scale for the Assessment of Negative Symptoms total scores also did not decrease significantly (P = 0.106) in either group; however, galantamine treatment was associated with a greater benefit in the SANS subfactor, alogia (P = 0.007). CONCLUSIONS: The lack of robust significant effects of galantamine on negative, and other symptom domains, may be due to the relatively low baseline level of these symptoms in the tested population. Galantamine may have some benefit on certain negative symptoms, particularly alogia. Studies specifically designed to address the issue of the efficacy of galantamine for negative symptoms are needed to confirm this observation.
RCT Entities:
OBJECTIVES:Galantamine is an acetylcholinesterase inhibitor and an allosteric modulator of the alpha4beta2 and alpha7 nicotinic receptors. There are several case reports describing the potential benefits of galantamine for negative symptoms associated with schizophrenia. This secondary analysis describes the effects of galantamine on psychopathology in people with schizophrenia. METHODS: Subjects with clinically stable chronic schizophrenia were randomized to adjunctive galantamine (24 mg/d) or placebo in a 12-week double-blind trial. Symptomatology was assessed with the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impression Scale. The Scale for the Assessment of Negative Symptoms (SANS) was used to measure negative symptoms. RESULTS: Eighty-six patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of schizophrenia or schizoaffective disorder taking a stable dose of antipsychotic medications were randomized to adjunctive treatment with study drug (galantamine, n = 42; placebo, n = 44); 73 subjects completed the study (galantamine, n = 35; placebo, n = 38). No significant differences were found on BPRS total score (P = 0.585) or BPRS subfactor scores. Scale for the Assessment of Negative Symptoms total scores also did not decrease significantly (P = 0.106) in either group; however, galantamine treatment was associated with a greater benefit in the SANS subfactor, alogia (P = 0.007). CONCLUSIONS: The lack of robust significant effects of galantamine on negative, and other symptom domains, may be due to the relatively low baseline level of these symptoms in the tested population. Galantamine may have some benefit on certain negative symptoms, particularly alogia. Studies specifically designed to address the issue of the efficacy of galantamine for negative symptoms are needed to confirm this observation.
Authors: N Durany; R Zöchling; K W Boissl; W Paulus; G Ransmayr; T Tatschner; W Danielczyk; K Jellinger; J Deckert; P Riederer Journal: Neurosci Lett Date: 2000-06-23 Impact factor: 3.046
Authors: C R Breese; M J Lee; C E Adams; B Sullivan; J Logel; K M Gillen; M J Marks; A C Collins; S Leonard Journal: Neuropsychopharmacology Date: 2000-10 Impact factor: 7.853
Authors: Yen Kuang Yang; Leann Nelson; Lakshmi Kamaraju; William Wilson; Joseph P McEvoy Journal: Neuropsychopharmacology Date: 2002-10 Impact factor: 7.853
Authors: Robert W Buchanan; Robert R Conley; Dwight Dickinson; M Patricia Ball; Stephanie Feldman; James M Gold; Robert P McMahon Journal: Am J Psychiatry Date: 2007-11-06 Impact factor: 18.112
Authors: Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero Journal: Schizophr Bull Date: 2017-07-01 Impact factor: 9.306
Authors: Ikwunga Wonodi; Hirekatur V Gopinath; Judy Liu; Helene Adami; L Elliot Hong; Robert Allen-Emerson; Robert P McMahon; Gunvant K Thaker Journal: Psychopharmacology (Berl) Date: 2011-05-03 Impact factor: 4.530
Authors: Stephen I Deutsch; Barbara L Schwartz; Nina R Schooler; Clayton H Brown; Richard B Rosse; Stephanie M Rosse Journal: Schizophr Res Date: 2013-06-13 Impact factor: 4.939
Authors: Deanna L Kelly; Robert P McMahon; Elaine Weiner; Douglas L Boggs; Dwight Dickinson; Robert R Conley; Robert W Buchanan Journal: Schizophr Res Date: 2008-06-11 Impact factor: 4.939
Authors: Dong-Jie Xie; Hai-Song Shi; Simon S Y Lui; Chuan Shi; Ying Li; Karen K Y Ho; Karen S Y Hung; Wen-Xiu Li; Zheng-Hui Yi; Eric F C Cheung; Ann M Kring; Raymond C K Chan Journal: Schizophr Bull Date: 2018-10-15 Impact factor: 9.306